4SC AG

4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs in Germany. Its products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase Ib/II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. Show More...

  • Website https://www.4sc.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 1.25 EUR
  • Last Updated 29-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share EUR -2.25 -1.99 -1.28 -0.93 -0.9 -0.61 -0.56 -0.43 -0.55 -0.41 -0.41
    Dividends EUR
    Payout Ratio % *
    Shares Mil 9.0 10.0 10.0 11.0 11.0 15.0 20.0 26.0 32.0 34.0 34.0
    Book Value Per Share * EUR 4.05 2.87 2.0 1.2 0.47 1.47 0.99 0.29 1.19 0.5 1.05
    Free Cash Flow Per Share * EUR -2.06 -1.39 -1.59 -0.77 -0.71 -0.64 -0.69 -0.53 -0.33 -0.51
    Return on Assets % -45.3 -57.3 -43.4 -45.01 -59.41 -38.11 -42.5 -32.73 -44.61 -33.16 -33.16
    Financial Leverage (Average) 1.11 1.35 1.33 1.57 7.28 1.27 1.25 1.07 1.1 1.1 1.24
    Return on Equity % -48.89 -69.67 -58.29 -63.6 -145.45 -64.81 -53.55 -36.55 -48.28 -36.43 -36.43
    Return on Invested Capital % -49.24 -70.54 -58.71 -63.84 -136.48 -58.56 -51.21 -36.59 -48.28 -34.73 -34.73
    Interest Coverage -716.89 -576.63 -41.22 -27.53 -469.17 -394.89 -394.89
    Current Ratio 5.52 4.75 4.5 1.7 0.89 4.01 3.67 15.06 9.41 14.63 5.62
    Quick Ratio 5.17 4.52 4.33 1.5 0.8 3.86 3.51 14.99 9.2 14.51 5.52
    Debt/Equity 0.03